Omnicell (NASDAQ:OMCL) Upgraded by Zacks Research to “Hold” Rating

Omnicell (NASDAQ:OMCL) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday, Zacks reports.

A number of other research analysts have also recently commented on OMCL. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Finally, Piper Sandler reissued an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Performance

Shares of OMCL stock opened at $33.88 on Monday. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.54 billion, a PE ratio of 40.33, a P/E/G ratio of 0.86 and a beta of 0.97. The company’s fifty day simple moving average is $39.06 and its 200-day simple moving average is $39.21. Omnicell has a 52 week low of $29.06 and a 52 week high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same period in the prior year, the company earned $0.45 EPS. The firm’s revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities research analysts anticipate that Omnicell will post 1.41 EPS for the current year.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently added to or reduced their stakes in the company. Nykredit A S purchased a new position in Omnicell in the 2nd quarter valued at about $26,000. Raymond James Financial Inc. purchased a new stake in shares of Omnicell during the second quarter worth about $26,000. Versant Capital Management Inc increased its position in shares of Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after acquiring an additional 294 shares during the last quarter. Clearstead Advisors LLC lifted its stake in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after acquiring an additional 1,218 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Omnicell in the fourth quarter worth about $58,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.